Merck (MRK) ended the recent trading session at $94.02, demonstrating a -0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.08%.

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Merck & Co. is making waves as an undervalued S&P 500 stock, boasting a forward P/E ratio of 10.52 and strong hedge fund ...

SeaStar Medical (Nasdaq: ICU) has been selected to receive the 2025 Corporate Innovator Award from the National Kidney ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

Merck & Co Inc. has become a top contender for the most profitable value stock, but it faces some challenges. Merck boasts a forward P/E ratio of 10.36 and TTM net income of $17.117 billion. Despite ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Drugmakers are urging the Trump administration and European Union officials to exempt medical goods from widening tariff wars, hoping to avert an ...

In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Multi Use Bioreactor Market is Segmented by Type (Manual, Automatic, Semi-Automatic), by Application (Pharmaceuticals, Scientific Research Institution). According to new survey, Global Multi Use ...